{"id":"https://openalex.org/W2590634852","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.553","title":"Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population","display_name":"Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2590634852","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.553","mag":"2590634852"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.553","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.553","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.553","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040117135","display_name":"William Irvin","orcid":"https://orcid.org/0009-0000-4033-9541","observed_orcids":["https://orcid.org/0009-0000-4033-9541","https://orcid.org/0000-0002-7402-5783"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. J. Irvin","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041777150","display_name":"LA Carey","orcid":"https://orcid.org/0000-0003-2388-4649","observed_orcids":["https://orcid.org/0000-0003-2388-4649"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. A. Carey","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101864985","display_name":"Oluwabukolami J. Olajide","orcid":"https://orcid.org/0000-0003-3882-9415","observed_orcids":["https://orcid.org/0000-0003-3882-9415"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"O. Olajide","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111928230","display_name":"E. Claire Dees","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. C. Dees","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010429902","display_name":"Jeffrey M. Peppercorn","orcid":"https://orcid.org/0000-0001-7138-6404","observed_orcids":["https://orcid.org/0000-0001-7138-6404"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Peppercorn","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060185754","display_name":"W. K. Chiu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. K. Chiu","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045371171","display_name":"C. M. Walko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. M. Walko","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111669228","display_name":"H. L. McLeod","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. L. McLeod","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. P. Evans","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. P. Evans","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018204002","display_name":"Karen E. Weck","orcid":"https://orcid.org/0000-0002-8516-333X","observed_orcids":["https://orcid.org/0000-0002-8516-333X"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. E. Weck","raw_affiliation_strings":["University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, NC; Rex Hematology Oncology Associates, Raleigh, NC; Duke University, Durham, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I170897317"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"553","last_page":"553"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyp2d6-genotyping","display_name":"CYP2D6 genotyping","score":0.9490000009536743},{"id":"https://openalex.org/keywords/tamoxifen","display_name":"tamoxifen","score":0.8270000219345093},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9700000286102295},{"id":"https://openalex.org/keywords/intermediate-metabolizers","display_name":"intermediate metabolizers","score":0.7770000100135803},{"id":"https://openalex.org/keywords/poor-metabolizers","display_name":"poor metabolizers","score":0.9959999918937683},{"id":"https://openalex.org/keywords/ultrarapid-metabolizers","display_name":"ultrarapid metabolizers","score":0.8539999723434448},{"id":"https://openalex.org/keywords/african-american-women","display_name":"African American women","score":0.7099999785423279},{"id":"https://openalex.org/keywords/multiracial-people","display_name":"multiracial population","score":0.7850000262260437},{"id":"https://openalex.org/keywords/ethnic-differences","display_name":"ethnic differences","score":0.30399999022483826}],"concepts":[{"id":"https://openalex.org/C31467283","wikidata":"https://www.wikidata.org/wiki/Q912147","display_name":"Genotyping","level":4,"score":0.7752134799957275},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7249035239219666},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.6910743713378906},{"id":"https://openalex.org/C33664856","wikidata":"https://www.wikidata.org/wiki/Q3271142","display_name":"CYP2D6","level":4,"score":0.6899445056915283},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6270390152931213},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.6059677600860596},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.5496514439582825},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5371947884559631},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5007388591766357},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.47012364864349365},{"id":"https://openalex.org/C37463918","wikidata":"https://www.wikidata.org/wiki/Q387981","display_name":"Allele frequency","level":4,"score":0.43537747859954834},{"id":"https://openalex.org/C55775858","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenetics","level":4,"score":0.4203704595565796},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3828728497028351},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.36105936765670776},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18531128764152527},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.09357869625091553},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.0},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.553","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.553","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.553","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.6499999761581421,"display_name":"No poverty","id":"https://metadata.un.org/sdg/1"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1994401414","https://openalex.org/W1514995717","https://openalex.org/W1980756636","https://openalex.org/W2073973349","https://openalex.org/W2113225995","https://openalex.org/W1993646007","https://openalex.org/W2013479777","https://openalex.org/W2138151507","https://openalex.org/W2069469265","https://openalex.org/W2162625234"],"abstract_inverted_index":{"553":[0],"Background:":[1],"CYP2D6":[2,39,64,255],"genotyping":[3,256],"has":[4],"been":[5,235],"suggested":[6],"to":[7,11,16,138,203],"avoid":[8],"suboptimal":[9],"responses":[10],"tamoxifen":[12,48],"(T).":[13,49],"Most":[14],"studies":[15],"date":[17],"are":[18,124],"in":[19,42,98,112,146,193],"white":[20],"patients":[21],"(pts)":[22],"and":[23,60,92,161,188,231,248],"focus":[24],"on":[25,55,62],"a":[26,197,207,258],"limited":[27],"number":[28],"of":[29,44,200,210,220,252,260,267],"genetic":[30],"variants.":[31],"In":[32,51,215],"this":[33,135,194,241],"clinical":[34],"trial,":[35],"we":[36,128],"comprehensively":[37],"examined":[38],"allele":[40,131],"frequencies":[41],"women":[43],"heterogenous":[45],"ethnicity":[46],"taking":[47],"Methods:":[50],"LCCC":[52],"0801,":[53],"pts":[54,99,113,144,211,222],"T":[56,94,121,239,246,261],"\u2265":[57],"4":[58,157],"months":[59],"not":[61,111],"potent":[63],"inhibiting":[65],"medications":[66],"were":[67],"genotyped":[68],"using":[69],"the":[70,130,147,217,250],"CYP450":[71],"AmpliChip":[72],"for":[73,115,245],"2D6":[74],"alleles:":[75],"*1-*11,":[76],"*15,":[77],"*17,":[78],"*19,":[79],"*20,":[80],"*29,":[81],"*35,":[82],"*36,":[83],"*40,":[84],"*41,":[85],"*1XN,":[86],"*2XN,":[87],"*4XN,":[88],"*10XN,":[89],"*17XN,":[90],"*35XN":[91],"*41XN.":[93],"dose":[95],"was":[96],"increased":[97],"with":[100,237],"any":[101],"intermediate":[102],"or":[103,107],"poor":[104],"metabolizing":[105,117],"(IM":[106],"PM)":[108],"alleles":[109,202],"[but":[110],"homozygous":[114],"extensive":[116],"(EM)":[118],"alleles].":[119],"Serial":[120],"metabolite":[122],"levels":[123],"being":[125],"assessed.":[126],"Here":[127],"report":[129],"frequency":[132,199],"data":[133],"from":[134],"study":[136],"compared":[137],"previously":[139],"published":[140],"cohorts.":[141],"Results:":[142],"108":[143],"participated":[145],"study:":[148],"24":[149],"(22%)":[150],"African-Americans":[151],"(AA),":[152],"76":[153],"(70%)":[154],"non-Hispanic":[155],"whites,":[156],"Asians,":[158],"3":[159],"Hispanics":[160],"1":[162,170,189],"Spanish":[163],"European.":[164],"Genotyping":[165],"revealed":[166],"28":[167],"(26%)":[168],"EM/EM,":[169],"EM/UM":[171],"(ultra-rapid),":[172],"29":[173],"(27%)":[174],"EM/IM,":[175],"22":[176],"(20%)":[177],"EM/PM,":[178],"8":[179],"(7%)":[180],"IM/IM,":[181],"10":[182],"(9%)":[183],"IM/PM,":[184],"9":[185],"(8%)":[186],"PM/PM":[187],"unknown.":[190],"Conclusions:":[191],"Pts":[192],"trial":[195],"had":[196],"similar":[198],"PM":[201,230],"previous":[204],"reports,":[205],"however":[206],"high":[208],"proportion":[209],"have":[212,234,243],"IM":[213,232],"alleles.":[214],"particular,":[216],"majority":[218],"(79%)":[219],"AA":[221],"possess":[223],"at":[224],"least":[225],"one":[226],"variant":[227],"allele.":[228],"Since":[229],"genotypes":[233],"associated":[236],"reduced":[238],"metabolism,":[240],"may":[242],"implications":[244],"efficacy":[247],"emphasizes":[249],"importance":[251],"trials":[253],"examining":[254],"as":[257],"determinant":[259],"use.":[262],"(Supported":[263],"by":[264],"Laboratory":[265],"Corporation":[266],"America,":[268],"Roche":[269],"Diagnostics,":[270],"NC":[271],"UCRF,":[272],"NCI":[273],"SPORE.)":[274],"[Table:":[275,278],"see":[276,279],"text]":[277,280]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}